SRR4195657
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.650
- BILE_ACID_METABOLISM+0.600
- FATTY_ACID_METABOLISM+0.580
- COAGULATION+0.540
- ADIPOGENESIS+0.500
- OXIDATIVE_PHOSPHORYLATION+0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
- TNFA_SIGNALING_VIA_NFKB+0.380
- CHOLESTEROL_HOMEOSTASIS+0.370
- PEROXISOME+0.370
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.560
- WNT_BETA_CATENIN_SIGNALING-0.480
- MYC_TARGETS_V2-0.380
- MITOTIC_SPINDLE-0.340
- HEDGEHOG_SIGNALING-0.290
- MYC_TARGETS_V1-0.290
- SPERMATOGENESIS-0.160
- APICAL_JUNCTION-0.150
- NOTCH_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR975594 | — | — | 0.952 |
| 2 | SRR11296843 | — | — | 0.928 |
| 3 | SRR4195645 | — | — | 0.913 |
| 4 | SRR15030885 | — | — | 0.891 |
| 5 | SRR4195682 | — | — | 0.881 |
| 6 | SRR8518286 | — | F | 0.878 |
| 7 | SRR15030845 | — | — | 0.876 |
| 8 | SRR4195672 | — | — | 0.857 |
| 9 | d2bd30d9-e0ce-4b80-889b-974bc0563d9c | — | — | 0.852 |
| 10 | 830ff04e-ebca-42d8-a018-0a49315640b5 | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.650 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.580 | Inavolisib | — uncovered |
| COAGULATION | 0.540 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| PEROXISOME | 0.370 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |